semaglutide approved FDA approves obesity drug that helped people cut weight 15% FDA Approves Semaglutide for Pediatric

Clinical Evidence on GLP-1 and Heart Rate Changes Major clinical trials evaluating semaglutide and tirzepatide documented heart rate increases in subgroups of participants

Patients often wonder whether their use of semaglutide will be revealed through routine blood work ordered by their primary care physician or specialist

Amneal Pharmaceuticals, Inc., a global pharmaceutical company, today announced the advancement of two key strategic initiatives

Stress that is experienced suddenly raises heart rate and blood pressure as well as gluconeogenesis, glycogenolysis, lipolysis, and hepatic glucose release

Since hair loss is already a concern with rapid weight loss and GLP-1 therapy, maintaining zinc levels is one modifiable factor that can help mitigate this side effect